AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Skye Bioscience, Inc. Director's Dealing 2018

Jul 23, 2018

34097_dirs_2018-07-23_bd911247-2a41-426c-9521-8ec7bce214b0.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Nemus Bioscience, Inc. (NMUS)
CIK: 0001516551
Period of Report: 2018-07-23

Reporting Person: Cesario Douglas A (CFO and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-23	Common Stock	A	643501	$0.00	Acquired	643501	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-23	Employee Stock Option (Right to Buy)	$0.245	A	1195073	Acquired	2028-07-23	Common Stock (1195073)	Direct

Footnotes

F1: 100% of the restricted stock award shall vest and be deliverable on April 23, 2020.

F2: 25% of the total number of shares subject to the option shall vest and become exercisable on July 23, 2018, and the remaining 75% of the total number of shares subject to the option shall vest and become exercisable 1/33rd on each of the next 33 months thereafter.